Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Kent

Showing results (91-100 of 268) with videos related to

Pageof 27
Sort By:
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 22, 2010
Paraoxonase 1 polymorphisms and ischemic stroke risk: A systematic review and meta-analysisIssa J Dahabreh, Georgios D Kitsios, David M Kent, et al.
Journal of Clinical Epidemiology|November 15, 2017
The proposed 'concordance-statistic for benefit' provided a useful metric when modeling heterogeneous treatment effectsDavid van Klaveren, Ewout W Steyerberg, Patrick W Serruys, et al.
The American Journal of Medicine|December 29, 2017
Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk ModelJenica N Upshaw, David van Klaveren, Marvin A Konstam, et al.
Stroke|October 28, 2006
Can multivariable risk-benefit profiling be used to select treatment-favorable patients for thrombolysis in stroke in the 3- to 6-hour time window?David M Kent, Harry P Selker, Robin Ruthazer, et al.
BMJ (Clinical Research Ed.)|February 21, 2015
Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention ProgramJeremy B Sussman, David M Kent, Jason P Nelson, et al.
Journal of the American College of Cardiology|September 23, 2008
Statins, low-density lipoprotein cholesterol, and risk of cancerAlawi A Alsheikh-Ali, Thomas A Trikalinos, David M Kent, et al.
Diabetes Care|June 24, 2016
Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets?Saeid Shahraz, Anastassios G Pittas, Christine M Lundquist, et al.
Diabetes Care|November 24, 2016
Response to Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets? Diabetes Care 2016;38: e145-e146Saeid Shahraz, Anastassios G Pittas, Christine M Lundquist, et al.
Medrxiv : the Preprint Server for Health Sciences|May 20, 2024
Potential clinical impact of predictive modeling of heterogeneous treatment effects: scoping review of the impact of the PATH StatementJoe V Selby, Carolien C H M Maas, Bruce H Fireman, et al.
The American Journal of Bioethics : AJOB|November 26, 2003
Testing therapies less effective than the best current standard: ethical beliefs in an international sample of researchersDavid M Kent, Makaya Mwamburi, Richard A Cash, et al.
Pageof 27

Showing results (91-100 of 268) with videos related to

Sort By:
Pageof 27
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 22, 2010
Paraoxonase 1 polymorphisms and ischemic stroke risk: A systematic review and meta-analysisIssa J Dahabreh, Georgios D Kitsios, David M Kent, et al.
Journal of Clinical Epidemiology|November 15, 2017
The proposed 'concordance-statistic for benefit' provided a useful metric when modeling heterogeneous treatment effectsDavid van Klaveren, Ewout W Steyerberg, Patrick W Serruys, et al.
The American Journal of Medicine|December 29, 2017
Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk ModelJenica N Upshaw, David van Klaveren, Marvin A Konstam, et al.
Stroke|October 28, 2006
Can multivariable risk-benefit profiling be used to select treatment-favorable patients for thrombolysis in stroke in the 3- to 6-hour time window?David M Kent, Harry P Selker, Robin Ruthazer, et al.
BMJ (Clinical Research Ed.)|February 21, 2015
Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention ProgramJeremy B Sussman, David M Kent, Jason P Nelson, et al.
Journal of the American College of Cardiology|September 23, 2008
Statins, low-density lipoprotein cholesterol, and risk of cancerAlawi A Alsheikh-Ali, Thomas A Trikalinos, David M Kent, et al.
Diabetes Care|June 24, 2016
Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets?Saeid Shahraz, Anastassios G Pittas, Christine M Lundquist, et al.
Diabetes Care|November 24, 2016
Response to Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets? Diabetes Care 2016;38: e145-e146Saeid Shahraz, Anastassios G Pittas, Christine M Lundquist, et al.
Medrxiv : the Preprint Server for Health Sciences|May 20, 2024
Potential clinical impact of predictive modeling of heterogeneous treatment effects: scoping review of the impact of the PATH StatementJoe V Selby, Carolien C H M Maas, Bruce H Fireman, et al.
The American Journal of Bioethics : AJOB|November 26, 2003
Testing therapies less effective than the best current standard: ethical beliefs in an international sample of researchersDavid M Kent, Makaya Mwamburi, Richard A Cash, et al.
Pageof 27